127 related articles for article (PubMed ID: 7499106)
1. Binding of a new multidrug resistance modulator, S9788, to human plasma proteins and erythrocytes.
Urien S; Nguyen P; Bastian G; Lucas C; Tillement JP
Invest New Drugs; 1995; 13(1):37-41. PubMed ID: 7499106
[TBL] [Abstract][Full Text] [Related]
2. Binding of a new vinca alkaloid derivative, S12363, to human plasma proteins and platelets. Usefulness of an erythrocyte partitioning technique.
Urien S; Bastian G; Lucas C; Bizzari JP; Tillement JP
Invest New Drugs; 1992 Nov; 10(4):263-8. PubMed ID: 1487399
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunoassay for the measurement of S9788 in serum and microdialysis samples.
Mackie CE; English HE; Lelievre E; Gordon BH; Génissel P; Robinson BV
J Pharm Biomed Anal; 1997 Apr; 15(7):917-28. PubMed ID: 9160258
[TBL] [Abstract][Full Text] [Related]
4. Effects of the binding of imipramine to erythrocytes and plasma proteins on its transport through the rat blood-brain barrier.
Riant P; Urien S; Albengres E; Renouard A; Tillement JP
J Neurochem; 1988 Aug; 51(2):421-5. PubMed ID: 3392536
[TBL] [Abstract][Full Text] [Related]
5. Distribution of moricizine in human blood: binding to plasma proteins and erythrocytes.
Yang JM; Chan K; Chiang WT
Ther Drug Monit; 1990 Jan; 12(1):59-64. PubMed ID: 1689514
[TBL] [Abstract][Full Text] [Related]
6. Binding of 5-methoxypsoralen to blood fractions. Influence of albumin and free fatty acids: an in vitro study.
Muret P; Makki S; Urien S; Agache P; Bechtel P; Tillement JP
Skin Pharmacol; 1993; 6(1):45-51. PubMed ID: 7683892
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
[TBL] [Abstract][Full Text] [Related]
8. Comparative binding of etretinate and acitretin to plasma proteins and erythrocytes.
Urien S; Claudepierre P; Meyer J; Brandt R; Tillement JP
Biochem Pharmacol; 1992 Nov; 44(9):1891-3. PubMed ID: 1449542
[TBL] [Abstract][Full Text] [Related]
9. Binding of bornaprolol to human serum proteins and blood cells.
Shastri RA; Barre J; Houin G; Hamberger C; Tillement JP
Int J Clin Pharmacol Ther Toxicol; 1986 Jul; 24(7):351-6. PubMed ID: 3733286
[TBL] [Abstract][Full Text] [Related]
10. Plasma protein binding and erythrocyte partitioning of nicardipine in vitro.
Urien S; Albengres E; Comte A; Kiechel JR; Tillement JP
J Cardiovasc Pharmacol; 1985; 7(5):891-8. PubMed ID: 2413297
[TBL] [Abstract][Full Text] [Related]
11. Binedaline binding to plasma proteins and red blood cells in humans.
Morin D; Zini R; Ledewyn S; Colonna JP; Czajka M; Tillement JP
J Pharm Sci; 1985 Jul; 74(7):727-30. PubMed ID: 4032243
[TBL] [Abstract][Full Text] [Related]
12. Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance.
Léonce S; Pierré A; Anstett M; Pérez V; Genton A; Bizzari JP; Atassi G
Biochem Pharmacol; 1992 Nov; 44(9):1707-15. PubMed ID: 1360210
[TBL] [Abstract][Full Text] [Related]
13. Binding of pyrimethamine to human plasma proteins and erythrocytes.
Rudy AC; Poynor WJ
Pharm Res; 1990 Oct; 7(10):1055-60. PubMed ID: 2281036
[TBL] [Abstract][Full Text] [Related]
14. Effect of S9788, cyclosporin A and verapamil on intracellular distribution of THP-doxorubicin in multidrug-resistant K562 tumor cells, as studied by laser confocal microspectrofluorometry.
Sebille S; Morjani H; Poullain MG; Manfait M
Anticancer Res; 1994; 14(6A):2389-93. PubMed ID: 7825978
[TBL] [Abstract][Full Text] [Related]
15. Competitive inhibition of photoaffinity labelling of P-glycoprotein by anticancer drugs and modulators including S9788.
Demmer A; Dunn T; Hoof T; Kubesch P; Tümmler B
Eur J Pharmacol; 1996 Nov; 315(3):339-43. PubMed ID: 8982674
[TBL] [Abstract][Full Text] [Related]
16. The antimalarial drug halofantrine is bound mainly to low and high density lipoproteins in human serum.
Cenni B; Meyer J; Brandt R; Betschart B
Br J Clin Pharmacol; 1995 May; 39(5):519-26. PubMed ID: 7669488
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacological properties of S9788, a new modulator of multidrug resistance].
Bull Cancer; 1994 Feb; 81(2):93-103. PubMed ID: 7894124
[TBL] [Abstract][Full Text] [Related]
18. Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.
Punt CJ; Voest EE; Tueni E; Van Oosterom AT; Backx A; De Mulder PH; Hecquet B; Lucas C; Gerard B; Bleiberg H
Br J Cancer; 1997; 76(10):1376-81. PubMed ID: 9374386
[TBL] [Abstract][Full Text] [Related]
19. Method for the analysis of S9788, a drug to reverse resistance to anticancer agents, in animal plasma and human plasma and serum by high-performance liquid chromatography with ultraviolet detection.
Bakes DM; Turner ND; Gordon BH; Hiley MP; Walther B; Lucas C
J Chromatogr; 1993 May; 615(1):117-26. PubMed ID: 8340450
[TBL] [Abstract][Full Text] [Related]
20. Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells.
Merlin JL; Marchal S; Ramacci C; Dieterlen A; Schultz G; Lucas C; Poullain MG; Berlion M
Cytometry; 1995 Aug; 20(4):315-23. PubMed ID: 7587719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
